US 11,986,463 B2
Combination therapy for the treatment of gastrointestinal stromal tumor
Daniel L. Flynn, Waltham, MA (US); Bryan D. Smith, Waltham, MA (US); and Anu Gupta, Waltham, MA (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Jul. 30, 2020, as Appl. No. 16/943,821.
Application 16/943,821 is a continuation of application No. PCT/US2019/016148, filed on Jan. 31, 2019.
Claims priority of provisional application 62/624,448, filed on Jan. 31, 2018.
Prior Publication US 2021/0145805 A1, May 20, 2021
Int. Cl. A61K 31/4375 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 45/06 (2013.01); A61P 35/04 (2018.01)] 11 Claims
OG exemplary drawing
 
1. A method of treating a tumor having one or more c-KIT mutations in a patient in need thereof, comprising administering to the patient:
an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl1-3-phenylurea, or a pharmaceutically acceptable salt thereof; and
an effective amount of one or more MAPKAP kinase inhibitors selected from the group consisting of trametinib, binimetinib, cobimetinib, and ulixertinib,
wherein the tumor is gastrointestinal stromal tumor (GIST).